GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » ROA %

Fusion Antibodies (LSE:FAB) ROA % : -76.80% (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Fusion Antibodies's annualized Net Income for the quarter that ended in Sep. 2024 was £-1.52 Mil. Fusion Antibodies's average Total Assets over the quarter that ended in Sep. 2024 was £1.97 Mil. Therefore, Fusion Antibodies's annualized ROA % for the quarter that ended in Sep. 2024 was -76.80%.

The historical rank and industry rank for Fusion Antibodies's ROA % or its related term are showing as below:

LSE:FAB' s ROA % Range Over the Past 10 Years
Min: -99.33   Med: -20.57   Max: 103.08
Current: -81.27

During the past 10 years, Fusion Antibodies's highest ROA % was 103.08%. The lowest was -99.33%. And the median was -20.57%.

LSE:FAB's ROA % is ranked worse than
77.64% of 1498 companies
in the Biotechnology industry
Industry Median: -35.335 vs LSE:FAB: -81.27

Fusion Antibodies ROA % Historical Data

The historical data trend for Fusion Antibodies's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies ROA % Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.35 -48.85 -22.34 -74.42 -99.33

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.17 -97.95 -131.75 -77.62 -76.80

Competitive Comparison of Fusion Antibodies's ROA %

For the Biotechnology subindustry, Fusion Antibodies's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Antibodies's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's ROA % distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's ROA % falls into.



Fusion Antibodies ROA % Calculation

Fusion Antibodies's annualized ROA % for the fiscal year that ended in Mar. 2024 is calculated as:

ROA %=Net Income (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=-2.226/( (2.062+2.42)/ 2 )
=-2.226/2.241
=-99.33 %

Fusion Antibodies's annualized ROA % for the quarter that ended in Sep. 2024 is calculated as:

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-1.516/( (2.42+1.528)/ 2 )
=-1.516/1.974
=-76.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Sep. 2024) net income data. ROA % is displayed in the 30-year financial page.


Fusion Antibodies  (LSE:FAB) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-1.516/1.974
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.516 / 2.414)*(2.414 / 1.974)
=Net Margin %*Asset Turnover
=-62.8 %*1.2229
=-76.80 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2024) net income data. The Revenue data used here is two times the semi-annual (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Fusion Antibodies ROA % Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Antibodies Business Description

Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers various antibody engineering services for all therapeutic and diagnostic antibody development stages. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022